RxDoctor Payments Data

Sean Mullally, MD

Hematology & Oncology · Northampton, MANPI 1427099001

Payments from drug & device makers

$9,688in general payments, 2019–2025

Across 24 payments — averaging $403.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Epizyme, Inc.$4K
  • Genentech, Inc.$4K
  • Johnson & Johnson$1K
  • E.r. Squibb & Sons, L.L.C.$26
  • Philips North America LLC$21
  • Bristol Myers Squibb$20
  • plus $12 from 1 others

What the payments were for

  • Consulting fees$1,27322%
  • Speaking & faculty fees$4,20074%
  • Food & beverage$1843%
  • Education$381%

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,688 in reported general payments places this provider in the 50th percentile of 374 hematology & oncology providers in Massachusetts.

See all hematology & oncology providers in Massachusetts

Medicare billing

Part B allowed, 2024
$437,379
Medicare patients
1,222
Services billed
4,432

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BrukinsaZanubrutinib16$240,681
TruqapCapivasertib11$225,099
IbrancePalbociclib11$162,122
CalquenceAcalabrutinib Maleate11$149,507
EliquisApixaban89$82,169
Imatinib Mesylate12$40,074
XareltoRivaroxaban35$25,526
Abiraterone Acetate26$13,741
Exemestane18$1,656
Letrozole76$1,230
Gabapentin26$882
Hydroxyurea25$706
Tamoxifen Citrate43$693
Dexamethasone32$671
Morphine Sulfate ErMorphine Sulfate12$610

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$1,134$25,52635 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 374 hematology & oncology providers in Massachusetts.

Other hematology & oncology in Northampton

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →